Featured Research

from universities, journals, and other organizations

Gentler Chemotherapy Before Stem Cell Transplant Causes Long-term Remission Of Follicular Lymphoma, Study Suggests

Date:
January 3, 2008
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial.

Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

The two patients who had relapsed after the treatment regained a complete response after additional therapy.

"Our results show that this approach may actually be curative of follicular lymphoma," says lead author Issa Khouri, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation. "No other treatments produce this type of response."

The traditional treatment before receiving a matched stem cell donation consists of higher-dose chemotherapy that kills the lymphoma cells and shuts down the patient's own blood-producing stem cells - a process called myeloablation. While waiting for the donor's stem cells to engraft in the bone marrow and to begin producing blood, patients are vulnerable to infection, bleeding, and anemia.

Early research by Khouri and colleagues indicated that using a nonmyeloablative chemotherapy approach could control the lymphoma while sparing patients the side effects of high-dose chemotherapy. The transplanted blood stem cells launch an immune system attack on the lymphoma, a process called graft-vs.-lymphoma immunity.

"Our early results were encouraging. But with follicular lymphoma you need a long follow-up to see if the results hold," Khouri says. "This disease tends to recur later on, sometimes years after chemotherapy."

All patients in the present trial have been followed for at least five years, some for up to nine years. Trial patients had received 2 to 7 different chemotherapy regimens. Eight had received transplants of their own stem cells. At transplantation, 29 were in partial remission and 18 were in complete remission.

All 47 achieved complete remission after receiving matched blood stem cells from donors. One patient relapsed at 18 months. After receiving a donor lymphocyte infusion, the patient began a continuous complete response at 24 months. The other patient relapsed at 20 months and was found to have graft failure. Since treatment with rituximab, this patient has been in complete remission for four years.

Seven patients died during the trial, none from follicular lymphoma, Khouri notes. The 40 remaining patients all remain in remission. Overall survival at six years is 85 percent and current progression-free survival is 83 percent.

Acute graft-vs.-host disease (GVHD) arose in 11 percent of patients. Another 51 percent had chronic graft-vs.-host disease. GVHD was treated with immunosuppressive therapy. Khouri notes that only five patients in the study group remain on immunosuppressive therapy.

Long-term follow-up also allowed researchers to thoroughly gauge side effects, or toxicity, of the non-myeloablative approach. "It reduces toxicity significantly," Khouri says. "Even elderly patients can have this done."

Patients received fludarabine, cyclophosphamide and rituximab for three days before transplantation. Tacrolimus and methotrexate were used to prevent graft-vs.-host disease.

Follicular lymphoma is a Non-Hodgkin lymphoma, with about 12,000 new cases diagnosed annually.

Co-authors with Khouri are Rima M. Saliba, Martin Korbling, Chitra Hosing, Luis Fayad, Ming S. Lee, Felipe Samaniego, Barry I. Samuels, Daniel Couriel, Fredrick Hagemeister, Peter McLaughlin and Richard Champlin, all of M. D. Anderson.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Gentler Chemotherapy Before Stem Cell Transplant Causes Long-term Remission Of Follicular Lymphoma, Study Suggests." ScienceDaily. ScienceDaily, 3 January 2008. <www.sciencedaily.com/releases/2007/12/071210163321.htm>.
University of Texas M. D. Anderson Cancer Center. (2008, January 3). Gentler Chemotherapy Before Stem Cell Transplant Causes Long-term Remission Of Follicular Lymphoma, Study Suggests. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2007/12/071210163321.htm
University of Texas M. D. Anderson Cancer Center. "Gentler Chemotherapy Before Stem Cell Transplant Causes Long-term Remission Of Follicular Lymphoma, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/12/071210163321.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
How Mt. Everest Helped Scientists Research Diabetes

How Mt. Everest Helped Scientists Research Diabetes

Newsy (Apr. 15, 2014) British researchers were able to use Mount Everest's low altitudes to study insulin resistance. They hope to find ways to treat diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins